This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Centessa Pharmaceuticals PLC ADR -0.24%
Envoy Medical, Inc. Class A -3.02%
FuboTV +4.06%
Humacyte, Inc. -6.77%
Live Nation Entertainment, Inc. -1.69%

Centessa Pharmaceuticals PLC ADR

CNTA

39.58

-0.24%

Envoy Medical, Inc. Class A

COCH

0.68

-3.02%

FuboTV

FUBO

12.56

+4.06%

Humacyte, Inc.

HUMA

0.61

-6.77%

Live Nation Entertainment, Inc.

LYV

157.42

-1.69%

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Needham analyst Ami Fadia downgraded Centessa Pharmaceuticals plc (NASDAQ:CNTA) from Buy to Hold. Centessa Pharmaceuticals shares closed at $27.58 on Monday. See how other analysts view this stock.
  • Baird analyst Joseph Vruwink downgraded Phreesia, Inc. (NYSE:PHR) from Outperform to Neutral and lowered the price target from $25 to $10. Phreesia shares closed at $11.41 on Monday. See how other analysts view this stock.
  • D. Boral Capital analyst Jason Kolbert downgraded Plus Therapeutics, Inc. (NASDAQ:PSTV) from Buy to Hold. Plus Therapeutics shares closed at $0.2146 on Monday. See how other analysts view this stock.
  • Jefferies analyst Stephen Volkmann downgraded Rockwell Automation, Inc. (NYSE:ROK) from Buy to Hold and cut the price target from $490 to $380. Rockwell Automation shares closed at $348.51 on Monday. See how other analysts view this stock.
  • Benchmark analyst Bruce D. Jackson downgraded Humacyte, Inc. (NASDAQ:HUMA) from Buy to Speculative Buy and slashed the price target from $10 to $1. Humacyte shares closed at $0.5745 on Monday. See how other analysts view this stock.

Considering buying CNTA stock? Here’s what analysts think:

Photo via Shutterstock

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.